New Alzheimer Drugs

A pharmaceutical company, Eli Lilly, has released what it calls “positive results” from phase 3 trials for its own candidate Alzheimer’s treatment, donanemab.

8 May 2023

Context: 

A pharmaceutical company, Eli Lilly, has released what it calls “positive results” from phase 3 trials for its own candidate Alzheimer’s treatment, donanemab.

About the News:

  • Eli Lilly said donanemab had “significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.” 
  • Eli Lilly has yet to publish the full results, which means the data has not been peer reviewed or independently verified.

Alzheimer’s Disease:

  • Alzheimer’s disease is a brain disorder that gets worse over time. 
  • It’s characterised by changes in the brain that lead to deposits of certain proteins. 
  • Alzheimer’s disease causes the brain to shrink and brain cells to eventually die. 
  • It is the most common cause of dementia — a gradual decline in memory, thinking, behaviour and social skills. These changes affect a person’s ability to function.

How does donanemab work?

  • Donanemab is not the first of its kind. As with similar antibody-based therapies such as lecanemab, donanemab is not a cure for Alzheimer’s.
  • It has antibodies that target different forms of amyloid-beta (Aβ) proteins that can clump together to form amyloid plaques in people’s brains, resulting in their congnitive decline. 
  • The drug aims to remove the plaques from the brain and slow the progression of the disease.

How does donanemab compare to lecanemab?

  • Eli Lilly’s press release suggests that donanemab slows cognitive decline by 35%. Lecanemab trial results showed it slowed cognitive decline by 27%.
  • Both drugs are given intravenously, but the doses are different — donanemab was given every four weeks and lecanemab every two weeks. 
  • Both drugs were only tested on people with early stages of Alzheimer’s. 
  • It is, therefore, unknown how effective the drugs are for people with more advanced forms of the disease.
  • Lecanemab is approved in the US, but it is still under evaluation by the FDA’s counterpart in Europe, the European Medicines Agency (EMA).
  • Donanemab is not yet approved for use in either the US or Europe.

News Source: Indian Express

Archive Calendar

Mon Tue Wed Thu Fri Sat Sun
 123
45678910
11121314151617
18192021222324
25262728293031

by month

SRIJAN MAINS

Need help preparing for UPSC or State PSCs?

Connect with our experts to get free counselling & start preparing

Aiming for UPSC?

Download Our App

      
Quick Revise Now !
AVAILABLE FOR DOWNLOAD SOON
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध
Quick Revise Now !
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध

<div class="new-fform">






    </div>

    Subscribe our Newsletter
    Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.
    *Promise! We won't spam you.
    Yes! I want to Subscribe.